This demonstrates that PRDM1 is detectable in stomach cancer in another independent cohort, and with up-to-date RNA sequencing on biopsy [78] or even liquid biopsy [79], the expression of PRDM1 could serve as a factor in the prediction of stomach cancer development and BET inhibitor treatment. This evidence concerns the gene DNER and gastric neoplasm.